Quest Laboratories Live Share Price Today, Share Analysis and Chart

About the company - Business Profile

Quest Laboratories Ltd. is a pharmaceutical company based in central India, primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations. The company operates within the ethical and generic medicine segments, producing various dosage forms including tablets, capsules, and liquid orals. Quest Laboratories focuses on therapeutic areas such as anti-infectives, analgesics, and gastrointestinal medicines.

Key Points

• Key Facts:
  • Founded Year: Incorporated in 1998.
  • Headquarters: Indore, Madhya Pradesh.
  • Stock Listing: Listed on the NSE SME (Emerging) platform.
  • Core Products: Tablets, capsules, liquid orals, ointments, and powders across diverse therapeutic categories.
• Operations and Resources:
  • Manufacturing Facility: The company operates a manufacturing plant located in the Pithampur Special Economic Zone (SEZ), Madhya Pradesh.
  • Integration: The facility is designed to handle multiple dosage forms under a single roof, ensuring streamlined production processes from raw material processing to final packaging.
  • Certifications: The plant is compliant with World Health Organization Good Manufacturing Practices (WHO-GMP) standards.
• Market and Significance:
  • Industries Served: Primarily healthcare and pharmaceuticals.
  • Geographical Reach: While headquartered in Madhya Pradesh, the company distributes its products across several states in India and has a growing focus on international markets, particularly in Africa and South-East Asia.
• Business Model and Expertise:
  • Quest Laboratories follows a hybrid business model comprising ethical branded generics and institutional sales (government tenders).
  • The company is recognized for its ability to produce high-volume essential medicines efficiently.
  • Revenue Breakdown (FY24):
    • Domestic Sales: Contributed approximately 85% of total revenue.
    • Exports: Accounted for the remaining 15%, with a strategic goal to increase this share through new registrations in emerging markets.
• Financial Highlights (Annual FY24):
  • Revenue from Operations: Approximately ₹80.50 crore.
  • EBITDA: ₹9.65 crore (Margin: ~12%).
  • Profit After Tax (PAT): ₹5.85 crore.
  • Earnings Per Share (EPS): ₹6.12.
• Product and Technology Advancements:
  • Key Products: Popular brands include Questclox (Amoxicillin & Cloxacillin) and Questmol (Paracetamol).
  • Expansion: The company recently expanded its liquid oral section to include specialized pediatric formulations.
• Employee and Organizational Structure:
  • Employee Count: Approximately 150+ permanent employees as of the latest filing.
  • Subsidiaries: Operates as a standalone entity with no major active subsidiaries reported in the latest annual filing.
• Strategic Initiatives and Future Outlook:
  • Capacity Expansion: Utilizing proceeds from its initial public offering (IPO) to modernize existing machinery and increase the production capacity of the OSD (Oral Solid Dosage) section.
  • Market Diversification: Seeking regulatory approvals in newer geographies to reduce dependency on the domestic market.
  • Research & Development: Increasing investment in R&D to develop complex generic formulations and specialty products.

References

1. Annual Report Mar 2025
2. Investor Presentation Nov 2025
3. Annual Report Jun 2025